The FDA identified a recall of smartphone apps for Dexcom (Nasdaq:DXCM) continuous glucose monitors as the most serious type.

Shares of DexCom (DXCM) declined 10% on Friday after investment firm Hunterbrook Capital disclosed a short position in the ...

DANVILLE, CA, UNITED STATES, April 13, 2023/EINPresswire.com/ -- GenieMD, Inc. (“GenieMD”), a leader in virtual care platform and services, recognized by Frost ...

Health and wellness platform FriskaAi announced an agreement with glucose monitoring specialist Dexcom to integrate data from Dexcom's G7 and G6 continuous glucose monitoring (CGM) systems into the ...

ARLINGTON, VA / ACCESS Newswire / August 13, 2025 / FriskaAi announced today an agreement with DexCom, Inc., the global leader in glucose biosensing, to integrate data from Dexcom G7 and Dexcom G6 ...

Shares of medical device company DexCom (NASDAQ:DXCM) fell 7.4% in the morning session after a short-seller report from Hunterbrook Capital alleged issues with the company's G7 glucose monitoring ...

Dexcom faces mounting scrutiny over G7 safety concerns, FDA violations, financial practices, and growing competition from ...

Cardiometabolic digital diagnostics company Nanowear announced a licensing and data partnership with glucose monitoring specialist Dexcom to integrate glucose data from the Dexcom G7 into its ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $99.3, a high estimate of $106.00, and a low estimate of $89.00. Marking an ...